These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 29208204

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J, Xue W, Qing X, Jing X, Hou J, Tian X, Guo Q, He X, Cai J.
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [Abstract] [Full Text] [Related]

  • 3. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
    Walsh RC, Everly JJ, Brailey P, Rike AH, Arend LJ, Mogilishetty G, Govil A, Roy-Chaudhury P, Alloway RR, Woodle ES.
    Transplantation; 2010 Feb 15; 89(3):277-84. PubMed ID: 20145517
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of BORTEZOMIB treatment for refractory acute antibody-mediated rejection-a pilot study.
    Slatinska J, Slavcev A, Honsova E, Hruba P, Kratochvilova I, Rohal T, Viklicky O.
    HLA; 2018 Dec 15; 92 Suppl 2():47-50. PubMed ID: 30168284
    [Abstract] [Full Text] [Related]

  • 5. Impact of active antibody-mediated rejection treatment on donor-specific antibodies in pediatric kidney transplant recipients.
    Kincaide E, Hitchman K, Hall R, Yamaguchi I, Ding Y, Crowther B.
    Pediatr Transplant; 2019 Dec 15; 23(8):e13590. PubMed ID: 31617318
    [Abstract] [Full Text] [Related]

  • 6. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients.
    Morrow WR, Frazier EA, Mahle WT, Harville TO, Pye SE, Knecht KR, Howard EL, Smith RN, Saylors RL, Garcia X, Jaquiss RD, Woodle ES.
    Transplantation; 2012 Feb 15; 93(3):319-24. PubMed ID: 22179403
    [Abstract] [Full Text] [Related]

  • 7. Antibody depletion strategy for the treatment of suspected antibody-mediated rejection in lung transplant recipients: Does it work?
    Vacha M, Chery G, Hulbert A, Byrns J, Benedetti C, Finlen Copeland CA, Gray A, Onwuemene O, Palmer SM, Snyder LD.
    Clin Transplant; 2017 Mar 15; 31(3):. PubMed ID: 27988971
    [Abstract] [Full Text] [Related]

  • 8. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
    Eskandary F, Bond G, Schwaiger E, Kikic Z, Winzer C, Wahrmann M, Marinova L, Haslacher H, Regele H, Oberbauer R, Böhmig GA.
    Trials; 2014 Apr 03; 15():107. PubMed ID: 24708575
    [Abstract] [Full Text] [Related]

  • 9. Subclinical Antibody-mediated Rejection After Kidney Transplantation: Treatment Outcomes.
    Parajuli S, Joachim E, Alagusundaramoorthy S, Blazel J, Aziz F, Garg N, Muth B, Mohamed M, Mandelbrot D, Zhong W, Djamali A.
    Transplantation; 2019 Aug 03; 103(8):1722-1729. PubMed ID: 30507740
    [Abstract] [Full Text] [Related]

  • 10. Reducing Donor-specific Antibody During Acute Rejection Diminishes Long-term Renal Allograft Loss: Comparison of Early and Late Rejection.
    Lichvar AB, Tremblay S, Leino AD, Shields AR, Cardi MA, Abu Jawdeh BG, Govil A, Kremer J, Cuffy M, Paterno F, Diwan T, Brailey P, Girnita A, Alloway RR, Woodle ES.
    Transplantation; 2020 Nov 03; 104(11):2403-2414. PubMed ID: 32000256
    [Abstract] [Full Text] [Related]

  • 11. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
    Gupta G, Abu Jawdeh BG, Racusen LC, Bhasin B, Arend LJ, Trollinger B, Kraus E, Rabb H, Zachary AA, Montgomery RA, Alachkar N.
    Transplantation; 2014 Jun 27; 97(12):1240-6. PubMed ID: 24937198
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antibody-Mediated Rejection Treatment With Bortezomib in Renal Transplant Recipients: A Single-Center 24-Month Follow-up Case Report.
    Bahena Méndez J, López Y López LR, Sebastián Díaz MA, Trejo Curiel I, Galindo-Lopéz R, Baca Córdova A, Wasung de Lay M, Vázquez Dávila RA, Zarate Rodríguez PA, Carmona-Escamilla MA.
    Transplant Proc; 2020 May 27; 52(4):1123-1126. PubMed ID: 32224016
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
    Cioni M, Nocera A, Tagliamacco A, Basso S, Innocente A, Fontana I, Magnasco A, Trivelli A, Klersy C, Gurrado A, Ramondetta M, Boghen S, Catenacci L, Verrina E, Garibotto G, Ghiggeri GM, Cardillo M, Ginevri F, Comoli P.
    Transpl Int; 2019 Jan 27; 32(1):38-48. PubMed ID: 30076765
    [Abstract] [Full Text] [Related]

  • 18. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D, Bach C, Staudner C, Böger CA, Bergler T, Banas B, Spriewald BM.
    Nephrol Dial Transplant; 2017 Apr 01; 32(4):730-737. PubMed ID: 28339671
    [Abstract] [Full Text] [Related]

  • 19. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
    Stuckey LJ, Kamoun M, Chan KM.
    Ann Pharmacother; 2012 Jan 01; 46(1):e2. PubMed ID: 22202499
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.